Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant acellular pertussis vaccine safety in adults
NCT06798831Phase 3Active, not recruiting
- Sponsor
- BioNet
- Start
- Feb 2025
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of paracetamol + caffeine in pertussis (2 arms), sponsored by BioNet. Primary endpoint: Adverse Drug Reactions at 28 days. Started Feb 2025; status: active, not recruiting.
02
Drugs
paracetamol + caffeine
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT06798831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06798831.